Aspirin 81 mg for Non-alcoholic Fatty Liver Disease

"According to the listed parameters, this trial is recruiting adults aged 18-69. Additionally, there are 48 studies open for minors and 476 trials with participants over 65 years of age."

"According to the clinicaltrials.gov portal, this experimental procedure is actively seeking participants and was first launched on September 12th 2019 before being updated most recently on February 23rd 2022."

"This trial seeks to recruit 80 adults between the ages of eighteen and sixty-nine that are diagnosed with nonalcoholic fatty liver. To be considered a suitable candidate, they must present hepatic steatosis supported either through imaging or biopsy without other causes of fat accumulation in the liver or excessive alcohol consumption. Additionally, early stage fibrosis (F2) needs to have been confirmed via recent biopsy or elastography/Fibroscan test; if not already performed then one will take place during screening visit."

"Affirmative, according to clinicaltrials.gov the trial is still actively recruiting patients. This investigation was first posted on September 12th 2019 and most recently updated on February 23rd 2022 - with a total of 80 participants needed from 1 medical centre."

"Aspirin 81 mg is the preferred intervention for percutaneous coronary interventions (PCI). It can also be utilized to alleviate inflammation, neck pain and other minor dental issues."

"Since 2005, the drug Aspirin 81 mg has gone through a rigorous clinical trial process. The initial study was conducted by Abbott in 15480 and eventually led to Phase 4 approval for this medication. At present, 168 studies are being done with Aspirin 81 mg throughout 1398 cities and 57 nations worldwide."